David Evanson and William Plovanic
Forbes.com, Spring, 2012
Going into the Q1/12 earnings season for diabetes and wound care companies, Canaccord Genuity medical devices analyst William Plovanic noted his long term buys in the field were DexCom (DXCM : NASDAQ : $9.97 | BUY), Insulet (PODD : NASDAQ : $18.35 | BUY), Derma Sciences (DSCI : NASDAQ : $9.67 | BUY).
He said, “We believe improvements in the broader economy, with consumer confidence and unemployment levels improving, may offset typical seasonality and therefore DexCom and Insulet may experience strong Q1/12 results.”
He added, “Alternatively, the broader wound care market is relatively insulated to economic pressures due to the non-discretionary nature of chronic wounds, and Derma Sciences is well positioned due to its differentiated advanced wound care portfolio and new product cycle.”